Izračunajte točne volumene rekonstitucije, inzulinske jedinice i doze po bočici za svaki peptid.
Selank is a synthetic heptapeptide (7 amino acids) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s. It is a synthetic analog of the naturally occurring immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro sequence derived from neuropeptide research. The full sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Selank was developed in Russia as an anxiolytic and nootropic compound and is approved in Russia and some CIS countries as a pharmaceutical drug (brand name Selank nasal spray, manufactured by Peptogen) for the treatment of generalized anxiety disorder, neurasthenia, and cognitive impairment. In Western countries it is used exclusively as a research peptide. It differs from benzodiazepines and other classical anxiolytics in that it produces anxiolytic effects without sedation, dependence, or significant tolerance development — properties that have driven intense research interest.
The peptide is notable for its rapid onset of action when administered intranasally, crossing the blood-brain barrier within minutes. Its half-life via the intranasal route is very short — measured in minutes rather than hours — which requires either multiple daily intranasal administrations or subcutaneous injection to extend duration of effect. Subcutaneous injection extends the effective window to several hours.
Selank's pharmacology is multifaceted and incompletely understood. Key characterized mechanisms include:
Selank dosing varies significantly by administration route. The intranasal route is the most common given its rapid onset and non-invasive nature; subcutaneous injection is used when longer duration of action is desired. Use the Selank Calculator to compute draw volumes for any dose and concentration.
Intranasal Selank provides rapid CNS entry via the olfactory and trigeminal nerve pathways. Due to the very short half-life (~minutes), intranasal dosing is typically repeated 2–3 times daily for sustained effect:
Total daily dose for intranasal use typically ranges from 0.25 mg to 0.75 mg. A 5 mg vial reconstituted with 2 mL BAC water yields 2.5 mg/mL; each 0.1 mL drop from a nasal dropper delivers approximately 0.25 mg.
Subcutaneous injection extends the active window to 4–6 hours per dose. A typical subcutaneous protocol:
Most Selank protocols run 4–8 weeks continuously. Unlike benzodiazepines, Selank does not produce physical dependence, and abrupt discontinuation does not cause withdrawal. However, cycling off for 2–4 weeks after each protocol is considered good practice to preserve receptor sensitivity. View Selank at BergdorfBio for purchasing options.
Selank arrives as lyophilized powder in 2 mg or 5 mg vials. It must be reconstituted with bacteriostatic water before use. For nasal administration, some researchers use sterile saline rather than BAC water to reduce mucosal irritation, though BAC water is more commonly available and effective.
For intranasal use, the reconstituted solution can be transferred to a clean nasal dropper or nasal spray bottle using a syringe and blunt cannula. Store the nasal applicator refrigerated when not in use.
Selank has a favorable safety profile based on decades of Russian clinical research and preclinical data. It is not associated with the abuse potential, sedation, or dependence seen with classical anxiolytics.
In Russian Phase I–II clinical trials, Selank showed no significant adverse effects at therapeutic doses. No evidence of mutagenicity, carcinogenicity, or toxicity has been found in preclinical studies.
The most widely used Russian nootropic stack combines Selank with Semax — a synthetic ACTH(4-7) analog with potent nootropic and neuroprotective properties. Selank provides anxiolytic grounding and BDNF support while Semax drives dopaminergic tone, focus, and serotonin metabolism. The combination is used in Russia clinically for cognitive decline, ADHD-adjacent presentations, and post-stroke rehabilitation.
For researchers interested in combining cognitive-stress optimization with metabolic enhancement, MOTS-c and Selank address entirely distinct biological targets. MOTS-c handles mitochondrial and metabolic signaling; Selank handles GABAergic tone, BDNF expression, and immune modulation. There is no known pharmacological conflict, and the two can be used in the same protocol with separate administration schedules.
For aging-related protocols targeting both neuroprotection and mitochondrial function, SS-31 can be layered with Selank. SS-31 addresses mitochondrial ROS and energy production; Selank addresses anxiety, cognitive performance, and neuroplasticity. Both have neuroprotective properties through different mechanisms, making the combination theoretically synergistic for brain health goals.
Benzodiazepines bind directly to GABA-A receptors as positive allosteric modulators with high affinity, producing sedation, muscle relaxation, and — with repeated use — physical dependence and tolerance. Selank modulates GABAergic tone indirectly and through multiple pathways, producing anxiolysis without sedation or dependence. Russian clinical studies found no withdrawal syndrome upon discontinuation of Selank, and no evidence of tolerance development over the studied timeframes.
In Russia and certain CIS countries, Selank is approved as a pharmaceutical nasal spray for anxiety and cognitive impairment. In the EU, US, UK, and most Western jurisdictions it is not approved for therapeutic use and is available only as a research peptide. Researchers should always verify the regulatory status in their jurisdiction.
Yes, and this is one of its most researched properties. Multiple studies have demonstrated improvements in memory consolidation, attention, and learning under Selank administration. The mechanism is closely tied to its BDNF-upregulating effects and its ability to reduce cortisol-driven cognitive interference — high anxiety impairs working memory and consolidation, and Selank's anxiolytic properties secondarily improve cognitive performance.
Some researchers report improved sleep quality, particularly reduced sleep-onset anxiety and fewer nighttime awakenings. The evening dose timing (30–60 minutes before bed) is a common protocol variation for sleep-focused applications. Unlike benzodiazepines, Selank does not suppress REM sleep, which is an important distinction for users prioritizing sleep architecture over simply inducing unconsciousness.
Intranasal delivery provides near-immediate CNS access via the olfactory nerve but has a very short duration — 20–40 minutes of peak effect. Subcutaneous injection slows systemic absorption and extends the active window to 3–6 hours per dose, making it more suitable for sustained cognitive or anxiolytic support throughout the day. Many researchers use intranasal for acute situational dosing (exam, presentation, high-stress event) and subcutaneous for daily protocol use.
No. This is a commonly noted distinction from SSRIs and anxiolytics like buspirone. Selank researchers consistently report that it reduces anxiety and stress reactivity without dampening emotional range or flattening affect. Positive emotions remain fully accessible, which is consistent with its mechanism of action — modulating stress responses rather than broadly suppressing neurotransmission.
Reconstituted Selank stored at 2–8°C is stable for approximately 28–30 days. For nasal use, a practical recommendation is to reconstitute smaller volumes (e.g., 1 mg vials into 1 mL) that can be used within 2 weeks, reducing the total time the solution is open and in a nasal applicator — which carries higher microbial exposure risk than a sealed vial.
Yes. Selank is commonly combined with racetam-class nootropics (aniracetam, piracetam), choline supplements (alpha-GPC, CDP-choline), and adaptogens (ashwagandha, rhodiola) without reported adverse interactions. For GABAergic supplements specifically (phenibut, L-theanine), caution is warranted to avoid excessive GABAergic tone, though Selank's modulatory — rather than direct agonist — mechanism makes significant negative interaction unlikely at standard doses.
Medical Disclaimer: The information on this page is provided for educational and research purposes only. Selank is not an approved drug or medical treatment in most jurisdictions. It is sold strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.
Pogledajte proizvod
Selank